Single ascending dose study of AQW051 in male Caucasians
Latest Information Update: 13 Dec 2013
At a glance
- Drugs VQW 765 (Primary)
- Indications Psychotic disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis
- 13 Dec 2013 New trial record
- 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.